BMO Capital keeps an Outperform rating and $40 price target on Structure Therapeutics (GPCR) while noting that the company’s top-line Phase 1b data for GBSR-1290 in healthy overweight/obese subjects was “firmly positive”. The lack of adverse effect-related discontinuations is promising and likely ahead of investor expectations, while the readout has accomplished the proof and concept and the competitiveness vs. Eli Lilly’s (LLY) orforglipro, the analyst tells investors in a research note. The firm also notes that Pfizer’s (PFE) danuglipron is now “further behind”.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GPCR:
- Structure Therapeutics announces $300M private placement
- Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
- Structure Therapeutics Announces $300 Million Private Placement Equity Financing
- Structure Therapeutics announces results from Phase 1b study of oral GLP-1
- Structure Therapeutics reports Q2 EPS (20c), consensus (28c)
Questions or Comments about the article? Write to editor@tipranks.com